Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SUE-HWA LIN and CHRISTOPHER J LOGOTHETIS.
SUE-HWA LIN
Connection Strength
4.645
CHRISTOPHER J LOGOTHETIS
  1. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61.
    View in: PubMed
    Score: 0.473
  2. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
    View in: PubMed
    Score: 0.333
  3. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
    View in: PubMed
    Score: 0.332
  4. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res. 2008 Mar 15; 14(6):1599-602.
    View in: PubMed
    Score: 0.328
  5. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005 Jan; 5(1):21-8.
    View in: PubMed
    Score: 0.262
  6. Endothelial-to-osteoblast transition in normal mouse bone development. iScience. 2023 Feb 17; 26(2):105994.
    View in: PubMed
    Score: 0.229
  7. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene. 2022 02; 41(6):757-769.
    View in: PubMed
    Score: 0.212
  8. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene. 2021 07; 40(27):4592-4603.
    View in: PubMed
    Score: 0.205
  9. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.186
  10. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res. 1999 Jan-Feb; 19(1A):337-40.
    View in: PubMed
    Score: 0.173
  11. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell. 2017 06 05; 41(5):467-480.e3.
    View in: PubMed
    Score: 0.155
  12. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59.
    View in: PubMed
    Score: 0.139
  13. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics. 2015 Mar; 14(3):471-83.
    View in: PubMed
    Score: 0.131
  14. Targeting constitutively activated ?1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013 Apr; 11(4):405-17.
    View in: PubMed
    Score: 0.115
  15. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate. 2012 Feb; 72(3):291-300.
    View in: PubMed
    Score: 0.103
  16. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010 Jun 01; 70(11):4580-9.
    View in: PubMed
    Score: 0.095
  17. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51.
    View in: PubMed
    Score: 0.095
  18. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008 Aug; 6(8):1259-67.
    View in: PubMed
    Score: 0.084
  19. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007 Jul 15; 67(14):6544-8.
    View in: PubMed
    Score: 0.078
  20. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10.
    View in: PubMed
    Score: 0.070
  21. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
    View in: PubMed
    Score: 0.061
  22. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2003 Aug 06; 95(15):1174-5; author reply 1175.
    View in: PubMed
    Score: 0.060
  23. Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer. Prostate. 2023 07; 83(10):950-961.
    View in: PubMed
    Score: 0.058
  24. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758.
    View in: PubMed
    Score: 0.056
  25. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs. 2002 Aug; 13(7):743-9.
    View in: PubMed
    Score: 0.055
  26. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13.
    View in: PubMed
    Score: 0.055
  27. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem. 2002 Sep 20; 277(38):35696-702.
    View in: PubMed
    Score: 0.055
  28. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.055
  29. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene. 2021 10; 40(41):6049-6056.
    View in: PubMed
    Score: 0.052
  30. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
    View in: PubMed
    Score: 0.050
  31. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel). 2020 Jan 19; 12(1).
    View in: PubMed
    Score: 0.047
  32. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther. 1999 Jul-Aug; 6(4):313-21.
    View in: PubMed
    Score: 0.045
  33. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.036
  34. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
    View in: PubMed
    Score: 0.034
  35. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81.
    View in: PubMed
    Score: 0.033
  36. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8.
    View in: PubMed
    Score: 0.032
  37. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 04; 99(9):1426-32.
    View in: PubMed
    Score: 0.021
  38. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710.
    View in: PubMed
    Score: 0.021
  39. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24; 27(5):596-603.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.